Hva skal skje for at den dobler seg? Bare ett godt Q3 eller må vi ha mer meldinger?
Ny CEO.
23 Likes
Nordic Nanovector Appoints Experienced Pharmaceutical Business Leader Erik Skullerud as Chief Executive Officer**
5 Likes
Jan H. Egberts, Chairman of Nordic Nanovector’s Board of Directors, said: "I am very pleased that Erik has agreed to join Nordic Nanovector. His commercial leadership experience combined with his knowledge of the oncology/haematology space will be vital as we evolve into a larger and more valuable business based on maximising the commercial potential of Betalutin®. I would like to thank Malene Brondberg for stepping up to the role of Interim CEO over the last few months, a period when the company has made good progress in delivering on its key objectives. Malene will continue in her role as CFO."
Mr Skullerud added: "I am very much looking forward to this new role at Nordic Nanovector. I believe my experience from around the world in strategy, commercialisation, and sales and marketing can help the company achieve the next important stage of its development as we work to bring Betalutin® to patients for the first time, a key step in realising the wider value of the business.”
19 Likes
Presentasjonen fra i dag på ABGSC Norwegian Oncology Seminar:
“As we draw closer to completing recruitment, we will be continuing the workflow around our CMC package and commercialisation strategy”
Denne setningen fra presentasjon i dag passer jo bra med meldingen som kom nå om ny CEO som har mye erfaring med å dra produkter fra klinisk og ut i markedet. 
“Mr Skullerud has launched numerous highly innovative products in therapeutic areas such as oncology, haematology, cardiology, and nephrology and he has significant business management exposure to EU, Asian and US markets. As a consultant he has worked with some of the world’s top pharma and biotech companies as well as small, highly specialised start-ups on projects ranging from corporate strategy, through early to mid-stage launch and commercialization to late-stage life cycle projects.”
23 Likes
Fra linken 
:
“Has been an integral part of building Amgen from a small biotech company to one of the largest in Europe.”
29 Likes
• We continue to refine our partnering strategy to enable the full potential of Betalutin® in NHL to be realised
6 Likes
Dette var fantastisk!
10 Likes
NANOV be like" falling down", hahaha
1 Like
Dette er rett mann til jobben! Stjernesignering.
Det deilige er at man mest sannsynlig får kjøpt nanov godt under 30kr i lang tid fremover. Lufta blåser fort ut av ballongen og stabiliserer seg rundt 20 hver gang. 
2 Likes
Tsja, Når nyheter kommer raskere enn lufta siver ut, da er ikke 30 et tak som holder lenge.
1 Like
Husk salgsordre på T minus 90 arbejdsdage
Bare å finne fram chartet,og begynne å tegne streker 
1 Like
Alright! Exactly what I was hoping for Will be interesting to see how the market accepts this news tomorrow !
2 Likes
NANO bliver styret af nogle shorter, men når de opgiver deres position, så kan vi får en opgang som holder. Dette kan ske hvis de leverer en god Q3 med indrulleringer omkring de 18-20 stk. Indtil videre tror jeg, at lidt opgang i de næste par dage og tilbage igen, desværre. Hvis de levere 18-20 indrullering ved Q3, har jeg bestullet på at gå tungt ind i aktien. Indtil videre lever jeg med mine beholdning, som den er.
2 Likes
Da ble det bayer, hadde en mistanke. Får ikke håpe alt blir solgt direkte nå. Fint med litt industri i Norge.
1 Like
Ny kaptein på skuta!
8 Likes
Se her ja.
Nå er Egbert lei av fjaset, og har garantert skrapt godt i kassen for å signere denne godbiten.
Spørs om ikke det borger for ett lite taktskifte utover høsten her.
Denne likte jeg godt på en tirsdag.
10 Likes